natgillin/translations-raw huggingface dataset:
Hirobriz Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators. 
Zdravilo Hirobriz Breezhaler vsebuje zdravilno učinkovino indakaterol iz skupine zdravil, ki jih imenujemo bronhodilatatorji.
In the event of deterioration of COPD during treatment with Hirobriz Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken. 
Če pride med zdravljenjem z zdravilom Hirobriz Breezhaler do poslabšanja KOPB, je treba ponovno pregledati bolnika in oceniti shemo zdravljenja KOPB.
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). 
Zdravilo Hirobriz Breezhaler je indicirano za vzdrževalno brohodilatatorno zdravljenje obstrukcije dihalnih poti pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).
Hirobriz Breezhaler has not been investigated in patients with not well controlled diabetes mellitus. 
Uporabe zdravila Hirobriz Breezhaler niso proučevali pri bolnikih, ki niso imeli dobro urejene sladkorne bolezni.
There are no data available for use of Hirobriz Breezhaler in patients with severe hepatic impairment. 
O uporabi zdravila Hirobriz Breezhaler pri bolnikih s hudo okvaro jeter ni na voljo nobenih podatkov.
Hirobriz Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function. 
Zdravilo Hirobriz Breezhaler je pri odmerjanju 150 mikrogramov in 300 mikrogramov enkrat na dan klinično pomembno izboljšalo pljučno funkcijo.
How to store Hirobriz Breezhaler Contents of the pack and other information 
Shranjevanje zdravila Hirobriz Breezhaler Vsebina pakiranja in dodatne informacije
Driving and using machines It is unlikely that Hirobriz Breezhaler will affect your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Po vsej verjetnosti zdravilo Hirobriz Breezhaler ne vpliva na vašo sposobnost upravljanja vozil in strojev.
What Hirobriz Breezhaler is and what it is used for 
Kaj je zdravilo Hirobriz Breezhaler in za kaj ga uporabljamo
Hirobriz Breezhaler has no or negligible influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Zdravilo Hirobriz Breezhaler nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Hirobriz Breezhaler at recommended therapeutic doses (see section 5.1). 
V kliničnih študijah pri uporabi zdravila Hirobriz Breezhaler v okviru terapevtskega odmerjanja niso opažali klinično pomembnih učinkov na podaljševanje intervala QTc (glejte poglavje 5.1).
What Hirobriz Breezhaler contains - Each Hirobriz Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate. 
Kaj vsebuje zdravilo Hirobriz Breezhaler - Ena kapsula zdravila Hirobriz Breezhaler 150 mikrogramov vsebuje 150 mikrogramov indakaterola v obliki indakaterolijevega maleata.
Hirobriz Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD). 
Za kaj uporabljamo zdravilo Hirobriz Breezhaler Zdravilo Hirobriz Breezhaler olajša dihanje odraslim bolnikom, ki imajo težave z dihanjem zaradi pljučne bolezni z imenom kronična obstruktivna pljučna bolezen (KOPB).
- Each Hirobriz Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate. 
- Ena kapsula zdravila Hirobriz Breezhaler 300 mikrogramov vsebuje 300 mikrogramov indakaterola v obliki indakaterolijevega maleata.
Talk to your doctor or pharmacist before using Hirobriz Breezhaler if you have asthma (in this case you should not use Hirobriz Breezhaler). 
Pred začetkom uporabe zdravila Hirobriz Breezhaler se posvetujte z zdravnikom ali farmacevtom: če imate astmo (v tem primeru ne smete uporabljati zdravila Hirobriz Breezhaler), če imate težave s srcem, če imate epilepsijo, če imate težave s ščitnico (hipertiroidizem), če imate sladkorno bolezen.
Hirobriz Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy. 
Zdravilo Hirobriz Breezhaler ni indicirano za zdravljenje akutnih epizod bronhospazma, t.j.
Only use the capsules with the inhaler provided in this pack (Hirobriz Breezhaler inhaler). 
Kapsule uporabljajte samo z inhalatorjem, ki je priložen v škatli (z inhalatorjem Hirobriz Breezhaler).
If you forget to inhale a dose, inhale just one dose at the usual time the next day. 
Če ste pozabili uporabiti zdravilo Hirobriz Breezhaler Če pozabite inhalirati odmerek, naslednji dan ob običajnem času inhalirajte samo en odmerek.
Immediate hypersensitivity reactions have been reported after administration of Hirobriz Breezhaler. 
Poročali so o primerih takojšnje preobčutljivostne reakcije po odmerjanju zdravila Hirobriz Breezhaler.
Hirobriz Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar. 
Kapsule Hirobriz Breezhaler 300 mikrogramov imajo nad modro črto z modro natisnjeno oznako "IDL 300", pod modro črto pa je z modro natisnjen zaščitni znak družbe ( ).
What Hirobriz Breezhaler looks like and content of the pack In this pack, you will find an inhaler, together with capsules in blister. 
Izgled zdravila Hirobriz Breezhaler in vsebina pakiranja Pakiranje vsebuje inhalator skupaj s kapsulami v pretisnih omotih.
When you start a new pack, use the new Hirobriz Breezhaler inhaler that is supplied in the pack. 
Ko odprete novo škatlo z zdravilom, začnite uporabljati tudi nov inhalator Hirobriz Breezhaler, ki je priložen pakiranju.
Hirobriz Breezhaler is a single-dose inhalation device. 
Hirobriz Breezhaler je inhalator za inhaliranje posameznih odmerkov.
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Hirobriz Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists. 
Kot velja za druge agoniste adrenergičnih receptorjev beta-2, je tudi pri indakaterolu potrebna previdnost pri uporabi pri bolnikih s kardiovaskularnimi boleznimi (s koronarno boleznijo, po akutnem miokardnem infarktu, z aritmijami, s hipertenzijo), pri bolnikih s konvulzivnimi motnjami ali s hipertiroidizmom in pri bolnikih, ki so neobičajno odzivni na agoniste adrenergičnih receptorjev beta-2, čeprav pri uporabi zdravila Hirobriz Breezhaler v okviru priporočenega odmerjanja običajno ni opaziti klinično pomembnih učinkov na kardiovaskularni sistem.
• Only use the Hirobriz Breezhaler inhaler contained in this pack. 
• Uporabljajte samo inhalator Hirobriz Breezhaler, ki je priložen temu pakiranju.
Hirobriz Breezhaler contains lactose 
Zdravilo Hirobriz Breezhaler vsebuje laktozo
INSTRUCTIONS FOR USE OF HIROBRIZ BREEZHALER INHALER 
NAVODILA ZA UPORABO INHALATORJA HIROBRIZ BREEZHALER
Carton containing 30 capsules and one Hirobriz Breezhaler inhaler. 
Škatla vsebuje 30 kapsul in en inhalator Hirobriz Breezhaler.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in an Hirobriz Breezhaler capsule. 
S pomočjo inhalatorja Hirobriz Breezhaler lahko inhalirate zdravilo, ki je v kapsuli Hirobriz Breezhaler.
Hirobriz Breezhaler capsules must not be swallowed. 
Kapsul Hirobriz Breezhaler se ne sme pogoltniti.
Carton containing 10 capsules and one Hirobriz Breezhaler inhaler. 
Škatla vsebuje 10 kapsul in en inhalator Hirobriz Breezhaler.
Show the pack of Hirobriz Breezhaler. 
Tam pokažite škatlo z zdravilom Hirobriz Breezhaler.
Never wash the Hirobriz Breezhaler inhaler with water. 
Inhalatorja Hirobriz Breezhaler nikoli ne umivajte z vodo.
At the recommended doses, the adverse reaction profile of Hirobriz Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation. 
Pri uporabi priporočenih odmerkov so bili med neželenimi učinki zdravila Hirobriz Breezhaler pri bolnikih s KOPB klinično nepomembni sistemski učinki beta-2-adrenergične stimulacije.
The usual dose is to inhale the content of one capsule each day. 
Koliko zdravila Hirobriz Breezhaler je treba uporabljati Običajni odmerek je inhaliranje vsebine ene kapsule vsak dan.
Do not store the capsules in the Hirobriz Breezhaler inhaler. 
Kapsul ne shranjujte v inhalatorju Hirobriz Breezhaler.
In this pack, you will find an inhaler and capsules (in blister) that contain the medicine as inhalation powder. 
Kako uporabljati zdravilo Hirobriz Breezhaler V škatli boste našli inhalator in kapsule (v pretisnih omotih), ki vsebujejo zdravilo v obliki praška za inhaliranje.
Reports of hypersensitivity have been received from post-approval marketing experience in association with the use of Hirobriz Breezhaler. 
Poročila o preobčutljivosti izhajajo iz izkušenj z uporabo zdravila Hirobriz Breezhaler po njegovem prihodu na trg.
Only use the Hirobriz Breezhaler inhaler contained in this pack. 
Uporabljajte samo inhalator Hirobriz Breezhaler, ki je priložen temu pakiranju.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Hirobriz Breezhaler Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in a capsule. 
S pomočjo inhalatorja Hirobriz Breezhaler boste lahko vdihnili (inhalirali) zdravilo, ki je v kapsuli.
Never place a Hirobriz Breezhaler capsule directly into the mouthpiece of the Hirobriz Breezhaler inhaler. 
Kapsule Hirobriz Breezhaler nikoli ne nameščajte neposredno na ustnik inhalatorja Hirobriz Breezhaler.
Never blow into the mouthpiece of the Hirobriz Breezhaler inhaler. 
Nikoli ne pihajte v ustnik inhalatorja Hirobriz Breezhaler.
How to use Hirobriz Breezhaler 
Kako uporabljati zdravilo Hirobriz Breezhaler
Always use the new Hirobriz Breezhaler inhaler that comes with your new pack. 
Vedno uporabljajte samo inhalator Hirobriz Breezhaler, ki je priložen novemu pakiranju.
The Hirobriz Breezhaler inhaler provided with each new prescription should be used. 
Vedno je treba uporabiti inhalator Hirobriz Breezhaler, ki je priložen novemu pakiranju zdravila.
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 150 mikrogramov prašek za inhaliranje, trde kapsule Hirobriz Breezhaler 300 mikrogramov prašek za inhaliranje, trde kapsule indakaterol
Never take the Hirobriz Breezhaler inhaler apart. 
Inhalatorja Hirobriz Breezhaler nikoli ne razstavljajte.
Always keep the Hirobriz Breezhaler inhaler and capsules in a dry place. 
Pazite, da bodo inhalator in kapsule Hirobriz Breezhaler vedno na suhem.
Hirobriz Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar. 
Kapsule Hirobriz Breezhaler 150 mikrogramov imajo nad črno črto s črno natisnjeno oznako
What Hirobriz Breezhaler is 
Kaj je zdravilo Hirobriz Breezhaler
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 300 mikrogramov prašek za inhaliranje, trde kapsule indakaterol
Breezhaler capsules with any other inhaler, and do not use Hirobriz Breezhaler inhaler to take any other capsule medicine. 
Hirobriz Breezhaler ne uporabljajte z nobenim drugim inhalatorjem, inhalatorja Hirobriz
• When you start a new pack, only use the new Hirobriz Breezhaler inhaler that is supplied in the pack. 
• Ko odprete novo škatlo z zdravilom, začnite uporabljati tudi nov inhalator Hirobriz Breezhaler,
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules 
Hirobriz Breezhaler 150 mikrogramov prašek za inhaliranje, trde kapsule
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules 
Hirobriz Breezhaler 300 mikrogramov prašek za inhaliranje, trde kapsule
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules indacaterol 
Hirobriz Breezhaler 150 mikrogramov prašek za inhaliranje, trde kapsule indakaterol
Other medicines and Hirobriz Breezhaler 
Shranjevanje zdravila Hirobriz Breezhaler
Do not swallow Hirobriz Breezhaler capsules. 
Kapsul Hirobriz Breezhaler ne smete pogoltniti.
700 micrograms 
700 mikrogramov Intravitrealni vsadek v aplikatorju
Intravitreal implant in applicator Intravitreal use pouch (foil) 1 pouch with applicator system 
Intravitrealna uporaba mošnjiček (folija)
This summary was last updated on 14 June 2012. 
Povzetek je bil nazadnje posodobljen 14/06/2012.
It may also reduce the use of antimicrobials in pig production units. 
Prav tako lahko zmanjša uporabo protimikrobnih sredstev pri rejo prašičev.
An increase in body temperature of up to 2°C may be observed on the day of vaccination. 
Na dan cepljenja je mogoče opaziti povišanje telesne temperature do 2°C.
Sows that have been vaccinated according to this scheme before need a single revaccination two to four weeks before the expected farrowing date. 
Svinje, ki so bile cepljene po tej shemi, je treba ponovno z enkratnim odmerkom cepiti dva do štiri tedne pred pričakovano prasitvijo.
The company has presented data from both laboratory and field studies on the effectiveness of the vaccine against the two bacteria. 
Družba je predstavila podatke o učinkovitosti cepiva proti obema bakterijama iz laboratorijskih in terenskih študij.
The European Commission granted a marketing authorisation valid throughout the European Union, for Porcilis ColiClos on 14 June 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Porcilis ColiClos, veljavno po vsej Evropski uniji, odobrila dne 14/06/2012.
A sometimes painful and hard swelling up to 10 cm in diameter may be observed at the injection site for up to 25 days. 
Včasih se na mestu injiciranje pojavi boleča in trda oteklina v premeru 10 cm, ki lahko traja do 25 dni.
The first injection is given to sows or gilts, six or eight weeks before the expected farrowing (giving birth) date and a second injection is given four weeks later. 
Prva injekcija se svinjam in mladicam daje šest ali osem tednov pred pričakovano prasitvijo (kotitvijo), druga pa štiri tedne po prvem.
The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption. 
Obdobje karence je čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje, meso, jajca ali mleko pa uporabijo za prehrano ljudi.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Porcilis ColiClos exceed the risks and recommended that Porcilis ColiClos be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Porcilis ColiClos večje od tveganj, in priporočil, da se zanj odobri dovoljenja za promet.
Other information about Porcilis ColiClos: 
Druge informacije o zdravilu Porcilis ColiClos:
Porcilis ColiClos is given by injection into a muscle in the neck area behind the ear. 
Cepivo Porcilis ColiClos se injicira v mišico na vratu v predelu za ušesom.
Porcilis ColiClos is a vaccine. 
Zdravilo Porcilis ColiClos je cepivo.
The withdrawal period for Porcilis ColiClos is zero days for pig meat. 
Obdobje karence za zdravilo Porcilis ColiClos za prašičje meso je nič dni.
Porcilis ColiClos contains an adjuvant to enhance the immune response. 
Zdravilo Porcilis ColiClos vsebuje adjuvans za povečanje imunskega odziva.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or the label shown to the physician. 
V primeru nenamernega samoinjiciranja takoj poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
Porcilis ColiClos is a vaccine that is available as a suspension for injection. 
Zdravilo Porcilis ColiClos je cepivo, ki je na voljo v obliki suspenzije za injiciranje.
When Porcilis ColiClos is given to sows or gilts, the pig's immune system recognises the inactivated bacteria as ‘foreign' and makes antibodies against them. 
Ko svinje in mladice prejmejo cepivo Porcilis ColiClos, njihov imunski sistem prepozna inaktivirane bakterije kot „tujke“ in proti njim razvije protitelesa.
What benefit has Porcilis ColiClos shown during the studies? 
Kakšne koristi je zdravilo Porcilis ColiClos izkazalo med študijami?
It contains parts of the Escherichia coli (E. coli) bacterium called fimbrial adhesins F4ab, F4ac, F5 and F6 and LT toxoid (weakened toxin), as well as toxoid of the Clostridium perfringens (C. perfringens) bacterium type C. 
Vsebuje dele bakterije Escherichia coli (E. coli), imenovane fimbrijski adhezini F4ab, F4ac, F5 in F6 ter toksoid LT (oslabljeni toksin) in toksoid bakterije Clostridium perfringens (C. perfringens) tipa C.
Porcilis ColiClos is given to sows (female pigs that have already given birth to piglets) or gilts (female pigs that have not yet given birth to piglets) to provide their offspring with protection against infections caused by E. coli strains that express the components F4ab, F4ac, F5 or F6, and by C. perfringens type C. The vaccine is used to reduce death and clinical signs of infections caused by these bacteria during the first days of life. 
Zdravilo Porcilis ColiClos se uporablja za svinje (samice, ki so že imele pujske) ali mladice (samice, ki še niso imele pujskov), da se njihove mladiče zaščiti pred okužbami, ki jih povzročajo sevi bakterije E.coli, ki izločajo komponente F4ab, F4ac, F5 ali F6, in bakterije C. perfringens tipa C. Cepivo se uporablja za zmanjšanje smrtnosti in kliničnih znakov okužb s temi bakterijami v prvih dneh po rojstvu.
These antibodies are transferred from the mother to the piglets through the colostrum (first milk), and they help the piglets to fight E. coli or C. perfringens infection if they become exposed after birth. 
Protitelesa se prenesejo prek kolostruma (prvega mleka) iz mame na pujske in jim pomagajo, da se spopadejo z okužbo z bakterijo E. coli ali C. perfringens, če so ji izpostavljeni po rojstvu.
To demonstrate protection against E.coli infection, studies were also presented with Porcilis Porcoli Diluvac Forte, a vaccine authorised within the EU with the same E. coli components as Porcilis ColiClos. 
Za dokaz zaščite proti okužbi z bakterijo E.coli so bile predstavljene tudi študije zdravila Porcilis Porcoli Diluvac Forte, tj. cepiva, ki je odobreno v EU in ima enake komponente bakterije E.coli, kot so prisotne v zdravilu Porcilis ColiClos.
What is the risk associated with Porcilis ColiClos? 
Kakšna tveganja so povezana z zdravilom Porcilis ColiClos?
Porcilis ColiClos has been shown to reduce death and the clinical signs of E. coli or C. perfringens infections such as neonatal piglet diarrhoea and necrotic enterotoxaemia (a severe infection of the intestines). 
Dokazano je bilo, da zdravilo Porcilis ColiClos zmanjšuje smrtnost in klinične znake okužb z bakterijami E. coli ali C. perfringens, kot sta neonatalna driska pri pujskih in nekrotična enterotoksemija (huda okužba črevesja).
Why has Porcilis ColiClos been approved? 
Zakaj je bilo zdravilo Porcilis ColiClos odobreno?
E. Coli and C. perfringens vaccine 
Porcilis ColiClos cepivo proti bakterijama E. Coli in C. perfringens
Reduced activity and lack of appetite on the day of vaccination commonly occurs. 
Prav tako se pogosto pojavi zmanjšana dejavnost in izguba teka.
Porcilis ColiClos contains parts of the bacteria E. coli and C. perfringens that have been inactivated so that they cannot cause disease. 
in C. perfringens, ki sta bili inaktivirani, tako da ne moreta povzročiti bolezni.
What is Porcilis ColiClos? 
Kaj je zdravilo Porcilis ColiClos?
How has Porcilis ColiClos been studied? 
Kako je bilo zdravilo Porcilis ColiClos raziskano?
What is Porcilis ColiClos used for? 
Za kaj se zdravilo Porcilis ColiClos uporablja?
How does Porcilis ColiClos work? 
Kako zdravilo Porcilis ColiClos deluje?
Treatment may be restarted once the patient's condition has stabilised. 
Zdravljenje lahko ponovno uvedete, ko se bo bolnikovo stanje stabiliziralo.
The review of SGLT2 inhibitors was initiated at the request of European Commission in June 2015, under Article 20 of Regulation (EC) No 726/2004. 
Pregled zaviralcev SGLT2 se je začel junija 2015 na zahtevo Evropske komisije v skladu s členom 20 Uredbe (ES) št. 726/2004.
The CHMP opinion was then sent to the European Commission, which issued a legally-binding decision valid throughout the EU. 
Mnenje odbora CHMP je bilo nato poslano Evropski komisiji, ki je izdala pravno zavezujočo odločbo, ki je veljavna po vsej Evropski uniji.
You may need emergency treatment and your diabetes medicine may need to be changed. 
Morda boste potrebovali intenzivno zdravljenje in bo treba vaše zdravilo za zdravljenje sladkorne bolezni zamenjati.
Healthcare professionals should be aware of possible atypical cases 
Zdravstveni delavci naj se zavedajo možnosti atipičnih primerov.
EMA's recommendations are based on an initial review by its Pharmacovigilance Risk Assessment Committee (PRAC). 
Priporočila agencije EMA temeljijo na začetnem pregledu, ki ga je opravil Odbor za ocenjevanje tveganja na področju farmakovigilance (PRAC).
An atypical presentation of diabetic ketoacidosis can delay diagnosis and treatment. 
Atipična oblika diabetične ketoacidoze lahko povzroči zamudo pri diagnosticiranju in zdravljenju.
• Inform patients of the signs and symptoms of diabetic ketoacidosis and advise them to seek medical advice immediately if they develop such signs and symptoms. 
• Bolnike poučite o znakih in simptomih diabetične ketoacidoze in jim svetujte, da v primeru pojava takih znakov in simptomov takoj poiščejo zdravniško pomoč.
• SGLT2 inhibitors in the EU are available under the following trade names: Ebymect, Edistride, Forxiga, Invokana, Jardiance, Synjardy, Vokanamet and Xigduo. 
• Zaviralci SGLT2 so v Evropski uniji na voljo pod naslednjimi trgovskimi imeni: Ebymect, Edistride, Forxiga, Invokana, Jardiance, Synjardy, Vokanamet in Xigduo.
• Diabetic ketoacidosis is a serious complication of diabetes. 
• Diabetična ketoacidoza je resen zaplet pri sladkorni bolezni.
The following SGLT2 inhibitors are authorised in the EU: Ebymect (dapagliflozin/metformin), Edistride (dapagliflozin), Forxiga (dapagliflozin), Invokana (canagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin / metformin), Vokanamet (canagliflozin / metformin) and Xigduo (dapagliflozin / metformin). 
V Evropski uniji so odobreni naslednji zaviralci SGLT2: Ebymect (dapagliflozin/metformin), Edistride (dapagliflozin), Forxiga (dapagliflozin), Invokana (kanagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin/metformin), Vokanamet (kanagliflozin/metformin) in Xigduo (dapagliflozin/metformin).
Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. 
Diabetična ketoacidoza je resen zaplet pri sladkorni bolezni, ki ga povzroči nizka raven insulina.
• If you have any of the symptoms above while taking an SGLT2 inhibitor, contact a doctor or the nearest hospital straightaway even if your sugar level is not particularly high. 
• Če jemljete zaviralec SGLT2 in imate katerega koli od zgoraj navedenih simptomov, se takoj posvetujte z zdravnikom ali najbližjo bolnišnico, tudi če vaša raven sladkorja ni zelo visoka.